Promising HAE pill trial cut short by low enrollment
Disease control
Terminated
This study tested three doses of an experimental oral drug, KVD824, to see if it could prevent swelling attacks in people with hereditary angioedema (HAE) types I and II. The trial was stopped early because not enough volunteers enrolled, so results are limited. The drug works by…
Phase: PHASE2 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated May 17, 2026 10:53 UTC